Raúl Ortíz

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression

Gloria Perazzoli, José Prados, Raúl Ortíz et al. · PLoS ONE · 2015 · 187 citations · Full text

Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications

Raúl Ortíz, Gloria Perazzoli, Laura Cabeza et al. · Current Neuropharmacology · 2020 · 161 citations · Full text

Nanotechnology Advances, Engineering, Biomedical Engineering +25

Nano-engineering of 5-fluorouracil-loaded magnetoliposomes for combined hyperthermia and chemotherapy against colon cancer

Beatriz Clares, Rafael A. Biedma-Ortiz, E Sáez-Fernández et al. · European Journal of Pharmaceutics and Biopharmaceutics · 2013 · 94 citations

Nanoparticles, Nanomedicine, Ferrofluid +11

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

Consolación Melguizo, José Prados, Beatríz González et al. · Journal of Translational Medicine · 2012 · 80 citations · Full text

Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells

Cristiano Farace, Jaime Antonio Oliver, Consolación Melguizo et al. · PLoS ONE · 2015 · 61 citations · Full text